Close menu




January 18th, 2024 | 08:30 CET

Morphosys on the verge of a short squeeze? Evotec share drops like a stone! Almonty Industries is exciting!

  • Mining
  • Tungsten
  • Biotechnology
  • Pharma
Photo credits: BMW Group

Share price disaster at Evotec. The shares of the German biotech company are falling like a stone in 2024 and have already lost over 30% of their value in just a few trading days. This results from the CEO's surprising resignation and delayed reports of insider transactions. "Manager-Magazin" added fuel to the fire with an article. Morphosys, on the other hand, is taking off. The blood cancer drug Pelabresib is causing speculation and price swings. Could there even be a short squeeze? The Almonty Industries share is also exciting at the moment. The shares of the raw materials company, which focuses on tungsten, appear to have bottomed out and are starting an upward trend. Operationally, Almonty is facing exciting times. Analysts expect the tungsten producer to more than triple its turnover between 2023 and 2025. Given the expected profit in the coming year, the share is anything but expensive.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: MORPHOSYS AG O.N. | DE0006632003 , EVOTEC SE INH O.N. | DE0005664809 , ALMONTY INDUSTRIES INC. | CA0203981034

Table of contents:


    Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG
    "[...] China's dominance is one of the reasons why we are so heavily involved in the tungsten market. Here, around 85% of production is in Chinese hands. [...]" Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

    Full interview

     

    Almonty Industries: Investors recognize opportunity

    We had already pointed out in December that the stock of Almonty Industries could see a breakthrough in 2024. And the start of the year has been successful. In a relatively weak environment overall, the tungsten producer's shares have already gained over 10% this year and are trading at CAD 0.62. The Canadian raw materials company with activities in Spain, Portugal and South Korea thus appears to have bottomed out and is now on an upward trend. There is a resistance zone between CAD 0.60 and CAD 0.67. If the breakout succeeds, it will be really exciting, as the share was already at CAD 0.86 at the beginning of 2023 and above CAD 1 in 2022. The analysts at the German Sphene Capital believe that the Almonty Industries share price could even reach CAD 1.69.

    The rise in stock price indicates that the Almonty story is gaining momentum. The tungsten producer is likely facing a pivotal year. In 2023, the Los Santos Mine in Spain underwent maintenance and was back in operation by the end of the year. Sphene analysts believe the mine will generate annual sales of over CAD 20 million. Almonty is currently working on expanding the Panasqueira mine in Portugal, aiming to double the annual tungsten oxide production of the Company's current cash cow and extend its service life. And then, of course, there is the Sangdong project. The mine in South Korea is to be commissioned this year, potentially becoming a game changer and positioning Almonty as a leading global producer of the critical metal tungsten. The development is co-financed by the German KfW. Of the committed loan volume of USD 75.1 million, USD 53.9 million has already been disbursed in several tranches. Thanks to these three cornerstones, analysts at Sphene Capital expect Almonty to be able to increase its turnover and profits to a new league. Sales are expected to more than triple from CAD 28.9 million last year to around CAD 100 million by 2025. In the coming year, Almonty should then be able to generate an after-tax profit of CAD 24.5 million - and the trend will continue upwards. At the current share price, the Company is valued at around CAD 145 million, suggesting that the share may have further room for growth.

    Evotec facing share price disaster

    Investors are currently abandoning Evotec shares. The milestone payment of USD 25 million by partner Bristol Myers Squibb is being overlooked. Instead, the surprising resignation of the long-standing CEO Werner Lanthaler, in conjunction with insider transactions published very late, is shaking investors' confidence. Numerous purchases and sales by Lanthaler from 2022 were only reported this year, raising concerns as such disclosures are typically expected within a few days. The "Manager-Magazin" adds fuel to the fire with an article titled "How the Evotec CEO Concealed Million-Dollar Deals for Years". According to the article, Lanthaler sold Evotec shares worth EUR 6 million before the partial exit of major shareholder Oetker became known and put the share under pressure. And according to the "Manager-Magazin," this is not the end of the story.

    The day before yesterday, the T. Rowe Price International Stock Fund announced that its stake in Evotec had fallen below the 5% threshold. Although the volume sold is limited, it could indicate that more prominent investors are also having doubts about the Company.

    The analysts at RBC also see reputational damage. Evotec itself may have published the insider transactions in good time but only received them from Lanthaler far too late. The analysts maintain their neutral assessment even after the share price slid from over EUR 21 to below EUR 14. For them, Evotec is a "Sector Perform" with a target price of EUR 18.60.

    Morphosys: Share on the verge of a short squeeze?

    Morphosys shares are at their highest level since the end of 2021. On Tuesday alone, it shot up by over 12% to EUR 38. That means the stock has more than doubled since the end of November 2023. However, there are also repeated double-digit price setbacks. Study data on the blood cancer drug pelabresib in November still seems to be fueling speculation. Is this speculation positive or negative? Even Morgan Stanley appears to be in two minds. Although the analysts see a sales potential of over USD 1 billion, they downgraded the share from "Overweight" to "Equal Weight". Short sellers are likely also contributing to the price fluctuations. The biotech company is popular among short sellers. If Morphosys shares continue to show relative strength or there is even positive news on pelabresib, a short squeeze is likely.


    The Morphosys share is traditionally not for the faint-hearted. The pipeline is manageable, and thus, the price swings caused by individual reports are high. Its popularity among short sellers is a constant source of excitement. This year will be exciting for Almonty. If the measures discussed for the three mines are implemented as presented and sales and earnings growth is initiated, significantly higher share prices are possible. Although Evotec could see a recovery rally at any time, the loss of confidence should not be underestimated, even if the Company itself is not to blame.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Armin Schulz on February 21st, 2024 | 07:30 CET

    Barrick Gold, Desert Gold, Renk - Golden times everywhere?

    • Mining
    • Gold
    • Defense

    The world is full of economic uncertainty and geopolitical tensions. These are ideal conditions for gold, which is still considered a safe haven. There are now several factors that point to a sustained upswing in gold prices. One factor is the increased involvement of central banks, which are increasing their reserves to an extent not seen for decades. Another factor is the discussion within the BRICS nations about introducing a new currency backed by gold as a counterweight to the dominant US dollar. Therefore, today, we look at two gold companies and shed light on Renk, a representative of the defense industry, which is also experiencing golden times.

    Read

    Commented by Juliane Zielonka on February 21st, 2024 | 07:15 CET

    Saturn Oil + Gas, Plug Power, Deutsche Pfandbriefbank - Energy shares and falling knives - where is it worth getting in?

    • Mining
    • Oil
    • Hydrogen
    • greenhydrogen
    • Banking

    The Canadian company Saturn Oil & Gas has announced its capital and operating budget plans for 2024. The main focus is on sustainable oil and gas production with high capital returns, a structured capital allocation and continuous rapid debt repayment. Plug Power is also gaining momentum and taking strong cost-saving measures to maintain its position at the forefront as a green hydrogen provider. Deutsche Pfandbriefbank (pbb) came under the spotlight last week as investors dumped shares due to its involvement in the US office real estate market. Is this bank a falling knife, or does this week offer a potential entry point? We provide the background.

    Read

    Commented by Fabian Lorenz on February 21st, 2024 | 07:00 CET

    Top news: BYD, Bayer and Globex Mining

    • Mining
    • Gold
    • Commodities
    • Electromobility
    • chemicals

    Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.

    Read